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Background: In eukaryotes, miR-16 is an important microRNA (miRNA) that is involved in numerous biological
processes. However, it is not fully understood how miR-16 executes its physiological functions. In the present study,
we aimed to identify novel miR-16 targets and study their biological functions.
Methods: Candidate target genes of miR-16 were screened by microarray analysis of mRNA levels in several cancer
cell lines with enhanced miR-16. Three bioinformatics algorithms, including TargetScan, PicTar, and miRanda, were
used in combination to calculate the miR-16 targets. The expression levels of miR-16 and target mRNA were
examined by relative quantification RT-PCR, and the expression levels of target protein were detected by Western
blot. Luciferase reporter plasmids were constructed to confirm direct targeting. The effect of miR-16 and target
gene on cell viability was evaluated using MTT assays. The effects of miR-16 and target gene on apoptosis and cell
cycle distribution were evaluated by flow cytometry analysis.
Results: By overexpressing miR-16 in several cancer cell lines and measuring global mRNA levels using microarray
analysis, we identified 27 genes that may be regulated by miR-16. After the bioinformatics filtering process, 18 genes
were selected as candidate miR-16 targets. Furthermore, we experimentally validated three of these candidates, MAP7
(microtubule-associated protein 7), PRDM4 (PR domain containing 4) and CDS2 (CDP-diacylglycerol synthase 2), as
direct targets of miR-16. Finally, we demonstrated that miR-16 targeting MAP7 played a critical role in regulating
proliferation but not apoptosis and cell cycle progression in cancer cells.
Conclusion: In summary, the present study identifies several novel miR-16 targets and illustrates a novel function of
miR-16 targeting MAP7 in modulating proliferation in cancer cells.
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microRNAs (miRNAs) are a class of endogenous non-
coding RNAs, typically 22 nucleotides in length, that
function primarily by targeting the 3′-untranslated re-
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reproduction in any medium, provided the ordirect mRNA degradation [1,2]. Through these post-
transcriptional gene regulation mechanisms, miRNAs
regulate a wide range of biological processes, including
cell proliferation and differentiation, migration, apop-
tosis, development and metabolism [1,2].
The number of miRNAs encoded by the genomes of
different organisms varies dramatically, and more than
2000 miRNAs have been identified in humans [1,2].
Some of these miRNAs have attracted special attention
for their involvement in the initiation, progression and
metastasis of human cancers [3-5]. One particularly
well-studied example is the ubiquitously expressed and
highly conserved miR-16, one of the first miRNAs to be. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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that miR-16 can modulate the cell cycle, inhibit cell pro-
liferation, promote cell apoptosis and suppress tumori-
genicity both in vitro and in vivo [7]. These effects can
be explained by several targets of miR-16: the anti-
apoptotic gene Bcl-2 (B-cell lymphoma 2) [8]; numerous
genes involved in the G1-S transition, such as cyclin D1,
cyclin D3, cyclin E1 and CDK6 (cyclin-dependent kinase
6) [9-11]; and genes involved in the Wnt signaling path-
way, such as WNT3A (wingless-type MMTV integration
site family, member 3A) [11]. Consistently, miR-16 is
frequently deleted and/or downregulated in many types
of cancer, such as chronic lymphocytic leukemia [6,12],
prostate cancer [11] and lung cancer [13].
Given the importance of miR-16 during tumorigenesis,
the aim of the present study is to identify new miR-16
targets and study their biological functions in cancer
cells. By overexpressing miR-16 in several cancer cell
lines and measuring global mRNA levels through
microarray platforms, we identified a large number of
transcripts that are potentially regulated by miR-16. We
further confirmed MAP7 (microtubule-associated pro-
tein 7), PRDM4 (PR domain containing 4) and CDS2
(CDP-diacylglycerol synthase 2) as direct targets of
miR-16. The mechanism through which miR-16 exe-




The human lung adenocarcinoma cell line A549, human
breast cancer cell line MCF-7, human epithelial car-
cinoma cell line HeLa, human colon adenocarcinoma
cell line SW480 and human embryonic kidney cell line
HEK-293 were purchased from the Shanghai Institute of
Cell Biology, Chinese Academy of Sciences (Shanghai,
China). These cells were maintained in RPMI 1640
medium (Gibco, CA, USA) or DMEM medium (Gibco)
supplemented with 10% fetal bovine serum (FBS) (Gibco).
Cells were grown at 37°C in a humidified atmosphere
with 5% CO2.
miR-16 overexpression or knockdown
miR-16 overexpression was achieved by transfecting
cells with pre-miR-16 (a synthetic RNA oligonucleotide
duplex mimicking miR-16 precursor), while miR-16
knockdown was achieved by transfecting cells with
anti-miR-16 (a chemically modified single-stranded
antisense oligonucleotide designed to specifically target
against mature miR-16). Scrambled negative control
RNA (pre-miR-control and anti-miR-control) served as
negative control. Synthetic RNA molecules, including pre-
miR-16, anti-miR-16 and scrambled negative control
RNA, were purchased from GenePharma (Shanghai,China). Cells were seeded on 60-mm dishes and were
transfected the following day using Lipofectamine 2000
(Invitrogen, Carlsbad, CA, USA) according to the manu-
facturer’s instructions. For each well, equal doses (200
pmol) of pre-miR-control, pre-miR-16, anti-miR-control
or anti-miR-16 were added. Cells were harvested 24 h
after transfection.
RNA isolation and relative quantification RT-PCR
Total RNA was extracted from the cultured cells using
TRIzol Reagent (Invitrogen) according to the manu-
facturer’s instructions. Assays to quantify mature miR-
16 were carried out using Taqman microRNA probes
(Applied Biosystems, Foster City, CA, USA) according
to the manufacturer’s instructions, with slight modifica-
tion. Briefly, 1 μg of total RNA was reverse-transcribed to
cDNA using AMV reverse transcriptase (TaKaRa, Dalian,
China) and a stem-loop RT primer (Applied Biosystems).
The reaction conditions were: 16°C for 30 min, 42°C for
30 min, 85°C for 5 min. Real-time PCR was performed
using a TaqMan PCR kit on an Applied Biosystems 7300
Sequence Detection System (Applied Biosystems). The re-
actions were incubated in a 96-well optical plate at 95°C
for 10 min, followed by 40 cycles of 95°C for 15 s and
60°C for 1 min. All reactions were run in triplicate.
After the reactions, the threshold cycles (CT) values
were determined using fixed threshold settings, and the
mean CT was determined from the triplicate PCRs. In the
experiments presented here, a comparative CT method
was used to compare each condition with controls.
miRNA expression in cells was normalized to that of the
U6 snRNA. The amount of miR-16 relative to the internal
control U6 was calculated with the equation 2−△ △CT, in
which △ △CT = (CT miR − 16 −CT U6)target − (CT miR − 16 −
CT U6)control.
For relative quantification RT-PCR analysis of MAP7,
PRDM4 and β-actin mRNA, 1 μg of total RNA was
reverse-transcribed to cDNA with oligo dT and
Thermoscript (TaKaRa, Dalian, China) in the reaction
conditions: 42°C for 60 min and 70°C for 10 min. Then
real-time PCR was performed on an Applied Biosystems
7300 Sequence Detection System (Applied Biosystems)
using SYBR green dye (Invitrogen). The 20-μl PCR reac-
tion included 1 μl RT product, 1 × QuantiTect SYBR
green PCR Master Mix, and 0.5 μM each sense and anti-
sense primers. The reactions were incubated in a 96-well
plate at 95°C for 5 min, followed by 40 cycles of 95°C for
30 s, 60°C for 30 s, and 72°C for 30 s. All reactions were
run in triplicate. After the reactions, the CT values were
determined using fixed threshold settings. The relative
amount of MAP7 and PRDM4 mRNA was normalized
to β-actin mRNA. The sequences of the primers are as
follows: MAP7 (sense): 5′-AAACTCTTTGTAACACC
ACCTGA-3′; MAP7 (antisense): 5′-GATGGAGATACA
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TGGTGGAAA-3′; PRDM4 (antisense): 5′-TAAGGTGG
TGGAGGTAGGGT-3′; β-actin (sense): 5′-AGGGAAAT
CGTGCGTGAC-3′; and β-actin (antisense): 5′-CGCTC
ATTGCCGATAGTG-3′.
Microarray procedures
The commercially available 22 K Human Genome Array
was purchased from the CapitalBio Corporation (Beijing,
China). Labeling, hybridization, washing, and scanning
were performed according to the standard operating
procedure provided by CapitalBio. Briefly, total RNA
was used to synthesize cDNA in an in vitro transcription
reaction. cDNA was fluorescently labeled by Cy5 or
Cy3-CPT using the Klenow enzyme. After hybridization,
non-specifically bound molecules were removed from
the microarray with two consecutive washes (0.2% SDS
and 2 × SSC at 42°C for 5 minutes followed by 0.2% SSC
for 5 minutes at room temperature). Subsequently, the ar-
rays were scanned with a LuxScan 10KA confocal laser
scanner (CapitalBio Corporation), and the obtained im-
ages were analyzed using LuxScan Version 3.0 (CapitalBio
Corporation) employing the LOWESS normalization
method.
miR-16 target prediction
The miRNA target prediction and analysis was performed
with the algorithms from TargetScan (http://www.targetscan.
org/) PicTar (http://pictar.mdc-berlin.de/) and miRanda
(http://www.microrna.org/).
Western blotting
MAP7 and PRDM4 protein levels were quantified by
western blot analysis of whole cell extracts using anti-
bodies against MAP7 and PRDM4. These samples were
normalized by blotting with an antibody against α-tubulin.
Anti-MAP7 (NBP1-46240) antibody was purchased from
Novus (CO, USA), and anti-PRDM4 (sc-15254) and
anti-α-tubulin (B-7) antibodies were purchased from
Santa Cruz Biotechnology (CA, USA).
Luciferase assay
The entire 3′-UTRs of human CDS2, PRDM4, MAP7,
PPP1R11, CHUK, LAMP2 and SLC35A4 were amplified
from human genomic DNA using PCR. The PCR prod-
ucts were inserted into the p-MIR-report plasmid
(Ambion). Efficient insertion was confirmed by sequen-
cing. For luciferase reporters containing mutant CDS2,
PRDM4 and MAP7 3′-UTRs, the sequences that inter-
act with bases 2–8 of the miR-16 seed sequence were
mutated. For luciferase reporter assays, cells were cul-
tured in 6-well plates, and each well was transfected
with 2 μg of firefly luciferase reporter plasmid, 2 μg of
β-galactosidase expression plasmid (Ambion), and equalamounts of scrambled negative control RNA, pre-miR-16,
or anti-miR-16 using Lipofectamine 2000 (Invitrogen).
The β-galactosidase plasmid was used as a transfection
control. At 24 h post-transfection, cells were assayed using
luciferase assay kits (Promega, Madison, WI, USA). The
data depicted are representative of three independent ex-
periments performed on different days.
Plasmid construction and siRNA interference assay
A mammalian expression plasmid encoding the human
MAP7 open reading frame (pReceiver-M02-MAP7) was
purchased from GeneCopoeia (Germantown, MD, USA).
An empty plasmid served as a negative control. The
siRNA (sequence: CAGAUUAGAUGUCACCAAUTT)
targeting human MAP7 cDNA was designed and synthe-
sized by Invitrogen (Carlsbad, CA, USA). A scrambled
siRNA (Stealth™ RNAi negative control kit, Invitrogen,
Carlsbad, CA, USA) that could not target human
MAP7 cDNA was included as a negative control. Plas-
mid and siRNA were transfected into A549 cells using
Lipofectamine 2000 (Invitrogen) according to the man-
ufacturer’s instructions. Total RNA and protein was
isolated at 24 h post-transfection. The MAP7 mRNA
and protein expression levels were assessed by relative
quantification RT-PCR and western blotting.
Cell viability assay
A549 cells were plated at 2.5 × 103 cells per well in 96-well
plates and incubated overnight in DMEM medium
supplemented with 10% FBS. After transfection, 20 μl 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium brom-
ide (MTT) (5 mg/mL) was added into a corresponding
test well and incubated for 4 h. The supernatant was then
discarded, and 200 μL of DMSO was added to each well
to dissolve the precipitate. Optical density (OD) was mea-
sured at a wavelength of 570 nm.
Apoptosis assays
Apoptosis was detected using an Annexin V-FITC/
propidium iodide (PI) staining assay. A549 cells were
cultured in 12-well plates and transfected with 40 pmol
of pre-miR-16 or siRNA of MAP7 to induce apoptosis.
Pre-miR-control and control siRNA served as negative
controls. Cells were cultured overnight with both serum-
containing complete medium and serum-depleted me-
dium; the attached cells and floating cells were then
harvested. Flow cytometry analysis of apoptotic cells was
carried out using an Annexin V-FITC/PI staining kit
(BD Biosciences, CA, USA). After washes with cold PBS,
the cells were resuspended in binding buffer (100 mM
HEPES, pH 7.4, 100 mM NaCl, and 25 mM CaCl2)
followed by staining with Annexin V-FITC/PI at room
temperature in darkness for 15 min. Apoptotic cells
were then evaluated by gating PI and Annexin V-
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(FACS) flow cytometer (BD Biosciences, San Jose, CA).
All experiments were performed in triplicate.
Cell cycle assay
Cells were harvested, washed once with PBS, and fixed in
70% ethanol overnight. Staining for DNA content was
performed with 50 mg/ml propidium iodide and 1 mg/ml
RNase A for 30 min. Analysis was performed on a FACS
flow cytometer (BD Biosciences) with Cell Quest Pro soft-
ware. Cell cycle modeling was performed with Modfit 3.0
software (Verity Software House, Topsham, ME).
Statistical analysis
All presented images of western blotting and cell cycle
assay are representative of at least three independent ex-
periments. Relative quantification RT-PCR, luciferase
reporter, and cell viability assays were performed in trip-
licate, and each experiment was repeated three to five
times. The data shown are the mean ± SD of at least
three independent experiments. Statistical significance
was considered at p < 0.05 using the Student’s t-test.
Results
The identification of candidate miR-16 targets by
microarray analysis and bioinformatics algorithms
Animal miRNAs were originally believed to block trans-
lational processes without affecting transcript levels
[1-3]. However, recent evidence has changed this view,
showing that target mRNA degradation is a widespread
effect of miRNA-based regulation that alone accounts
for most of the repression mediated by miRNAs in
mammalian cell cultures [14]. Inspired by this mode of
miRNA action, we postulated that the high-throughput
mRNA microarray assays capable of detecting such ef-
fects at the mRNA level would provide a promising av-
enue for miRNA target identification. Considering that
miR-16 is a ubiquitously expressed miRNA frequently
downregulated in many types of cancer, we chose several
cell lines with very different origins for microarray
analysis to identify the common targets of miR-16. The
selected human cell lines included A549 (lung adenocar-
cinoma cell), MCF-7 (breast cancer cell), HeLa (epithe-
lial carcinoma cell), SW480 (colon adenocarcinoma cell)
and HEK-293 (embryonic kidney cell). We transfected
A549, MCF-7, HeLa, SW480 and HEK-293 cells with equal
doses of pre-miR-16 (miRNA mimic) or pre-miR-control
(scrambled miRNA mimic, as a negative control) and
then surveyed mRNA transcripts that were inversely
expressed relative to miR-16 using microarray analysis.
The results showed that although most mRNAs were
not influenced by transfection with miR-16, some
mRNAs were downregulated in pre-miR-16-transfected
cells compared with control cells (Figure 1). To reducethe false positive rate and obtain a more accurate as-
sessment of the genuine miR-16 targets, only the
mRNAs that were downregulated by a factor of at least
1.5 (0.66-fold downregulation) in at least four cell lines
were considered as putative miR-16 targets. Finally, 27
mRNAs were selected for further analysis (Table 1).
Next, three algorithms, including TargetScan [15],
PicTar [16], and miRanda [17], were used in combination
to calculate whether the downregulated mRNAs were
candidate miR-16 targets. Only the mRNAs predicted as
miR-16 targets by at least two of the above-mentioned al-
gorithms were considered positive. In total, 18 mRNAs
were identified as candidate miR-16 targets (Table 2).
Identification of direct miR-16 targets by luciferase
reporter screening
However, transcript-based expression analysis and com-
putational predictions alone cannot directly measure the
actual miRNA-target interaction. Therefore, a luciferase
reporter assay was conducted to screen for target genes
that were directly controlled by miR-16 through the 3′-
UTR. Three genes, including MAP7, PRDM4 and CDS2,
were selected. The predicted interaction between miR-
16 and these genes is illustrated in Figure 2A. The entire
3′-UTRs of these genes were fused into a downstream
position of the firefly luciferase gene in a reporter plas-
mid. Luciferase reporters containing the 3′-UTRs of
PPP1R11 (protein phosphatase 1 regulatory subunit 11),
CHUK (conserved helix-loop-helix ubiquitous kinase),
LAMP2 (lysosomal-associated membrane protein 2) and
SLC35A4 (solute carrier family 35, member A4) were
generated and served as negative controls (PPP1R11,
LAMP2 and SLC35A4 contain putative miR-16 binding
sites but were not significantly altered by transfection
with miR-16, while CHUK does not have a candidate
miR-16 binding sequence). The resulting plasmids were
transfected into A549 cells combined with pre-miR-16
or pre-miR-control. The luciferase activities were as-
sayed 36 h after transfection. As shown in Figure 2B,
overexpression of miR-16 significantly decreased the lu-
ciferase activities of the reporter containing the 3′-UTRs
of MAP7, PRDM4 and CDS2, whereas the negative con-
trol reporters were unaffected by miR-16 in A549 cells.
Furthermore, we introduced point mutations into the
corresponding seed complementary sites in the 3′-UTR of
MAP7, PRDM4 and CDS2 to eliminate the predicted
binding by miR-16 (Figure 2A). Luciferase reporters
containing either wild-type or mutant MAP7, PRDM4
and CDS2 3′-UTRs were co-transfected with pre-miR-16,
pre-miR-control, anti-miR-16 (miRNA antisense) or anti-
miR-control (scrambled miRNA antisense as negative
control) into A549 cells. While the overexpression of miR-
16 decreased the luciferase activity, the inhibition of miR-
16 resulted in a significant increase in the luciferase
Figure 1 Scatter plots showing mRNA expression in pre-miR-16-transfected cells versus control cells. A549, MCF-7, HeLa, SW480 and HEK-
293 cells were seeded on 60-mm dishes and transfected the following day with Lipofectamine 2000. For each well, 200 pmol of pre-miR-16 or
pre-miR-control were added. At 24 h post-transfection, mRNA from these cells was subjected to microarray analysis.
Yan et al. Molecular Cancer 2013, 12:92 Page 5 of 11
http://www.molecular-cancer.com/content/12/1/92activity, and mutations in the seed complementary sites al-
most fully rescued the repression of reporter activity by
miR-16 (Figure 2C). These results demonstrate that miR-
16 can directly recognize the 3′-UTRs of MAP7, PRDM4
and CDS2 and mediate the post-transcriptional inhibition
of these genes.The downregulation of MAP7 and PRDM4 expression by
miR-16
We then determined whether the overexpression or knock-
down of miR-16 had an impact on MAP7 and PRDM4 ex-
pression. We transfected A549, HeLa and MCF-7 cells with
equal doses of pre-miR-16, pre-miR-control, anti-miR-16 or
Table 1 mRNAs identified as downregulated in cells
overexpressing miR-16
Gene name A549 MCF-7 Hela SW480 HEK-293 Mean fold
ARL2 0.4438 0.3506 0.5400 0.1817 0.3790
CDS2 0.5127 0.3022 0.5133 0.3045 0.4082
ANAPC13 0.3843 0.6239 0.3393 0.4607 0.4520
NUPL1 0.3315 0.6230 0.5340 0.3525 0.4602
MAP7 0.6168 0.4428 0.6220 0.5151 0.2027 0.4799
ARG2 0.4384 0.5793 0.4731 0.4845 0.4938
RTN4 0.6063 0.4024 0.5277 0.4415 0.4945
RARS 0.6351 0.4953 0.5922 0.2686 0.4978
PRDM4 0.6458 0.3892 0.5288 0.3809 0.5978 0.5085
SPRYD3 0.6232 0.3945 0.6387 0.5158 0.3778 0.5100
ATF6 0.5601 0.5654 0.5141 0.4159 0.5139
TMEM109 0.5647 0.5863 0.4650 0.4396 0.5139
RPS6KA3 0.5621 0.4471 0.6515 0.5522 0.3611 0.5148
BCR 0.6217 0.5980 0.4826 0.3719 0.5185
KIF3B 0.6569 0.5500 0.5970 0.3850 0.4665 0.5311
ENTPD6 0.5493 0.5145 0.5929 0.4446 0.5748 0.5352
CCND3 0.4777 0.5767 0.4867 0.6042 0.5363
ARHGDIA 0.5038 0.6295 0.5048 0.5103 0.5371
GABARAPL1 0.5492 0.6459 0.6228 0.3693 0.5468
PLEKHB2 0.4670 0.6040 0.5178 0.6149 0.5509
FLJ11149 0.4721 0.6577 0.6297 0.5081 0.5669
DNAJC5 0.5794 0.6497 0.4857 0.5730 0.5720
ZNF622 0.6543 0.6059 0.6394 0.4159 0.5789
ANXA11 0.6548 0.5811 0.4592 0.6410 0.5840
VPS33B 0.6586 0.6122 0.5394 0.5359 0.5865
ANLN 0.4597 0.6433 0.6247 0.6247 0.5881
PTH2 0.5264 0.6352 0.5819 0.6600 0.6009
Table 2 Candidate miR-16 targets predicted by
TargetScan, PicTar and miRanda
Gene name TargetScan PicTar miRanda Result
ARL2 4 5 1 Positive
CDS2 2 2 1 Positive
ANAPC13 1 0 0
NUPL1 0 0 0
MAP7 2 2 2 Positive
ARG2 0 0 0
RTN4 1 0 1 Positive
RARS 0 0 0
PRDM4 1 1 1 Positive
SPRYD3 4 0 2 Positive
ATF6 1 0 1 Positive
TMEM109 2 0 2 Positive
RPS6KA3 2 0 1 Positive
BCR 1 1 1 Positive
KIF3B 1 0 1 Positive
ENTPD6 2 0 0
CCND3 2 0 1 Positive
ARHGDIA 4 5 1 Positive
GABARAPL1 3 0 2 Positive
PLEKHB2 2 0 0
FLJ11149 0 0 0
DNAJC5 2 0 0
ZNF622 1 1 1 Positive
ANXA11 1 0 1 Positive
VPS33B 2 0 1 Positive
ANLN 1 0 1 Positive
PTH2 0 0 0
Numbers in the table indicate the putative binding sites of miR-16 in the
3′-UTR of target genes.
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MAP7 mRNA by relative quantification RT-PCR at
24 h post-transfection. The expression of miR-16 was
abolished by the introduction of anti-miR-16, whereas
pre-miR-16 significantly increased miR-16 levels in
A549, HeLa and MCF-7 cells (Figure 3, A, D and G).
Cells transfected with pre-miR-16 showed reduced
levels of MAP7 mRNA relative to cells transfected with
pre-miR-control; in contrast, the expression levels of
MAP7 mRNA were significantly increased in anti-miR-16-
transfected cells compared with those transfected with
anti-miR-control (Figure 3, B, E and H). Furthermore, we
repeated the above experiments and determined the ex-
pression of MAP7 protein by western blotting at 24 h
post-transfection. The expression levels of the MAP7 pro-
tein were significantly abolished by the introduction of
pre-miR-16, whereas cells transfected with pre-miR-con-
trol maintained a considerable amount of MAP7 protein;
in contrast, anti-miR-16 significantly increased the expres-
sion levels of MAP7 protein in A549, HeLa and MCF-7cells (Figure 3, C, F and I). Moreover, we found that the
PRDM4 mRNA and protein levels were inversely corre-
lated to miR-16 in A549 cells (Additional file 1: Figure S1,
A and B). These results demonstrate that miR-16 regulates
the expression of MAP7 and PRDM4 at both the tran-
script and protein levels.
The role of miR-16 in regulating MAP7 during
tumorigenesis
We next focused on studying the role of miR-16 in regu-
lating MAP7 and PRDM4. Because miR-16 is known to
be involved in regulation of proliferation, apoptosis and
cell cycle progression, we investigated whether the
overexpression or knockdown of miR-16, MAP7 or
PRDM4 would have an impact on these cellular pheno-
types in A549 cells. To knock down MAP7 and PRDM4,
siRNAs against MAP7 or PRDM4 were transfected into
A549 cells. To overexpress MAP7 and PRDM4, recom-
binant plasmids designed to specially express the full-
Figure 2 Identification of direct miR-16 targets by luciferase reporter screening. (A) Schematic description of the hypothetical duplexes
formed by interactions between miR-16 and the wild-type (WT) or mutant (MUT) 3′-UTRs of CDS2, PRDM4 and MAP7. For WT 3′-UTRs, perfect
base pairing between the “seeds” (the core sequence that encompasses the first 2–8 bases of the mature miRNA) and cognate targets was
noted. For MUT 3′-UTRs, the sequence that interacts with the 2–8 bases of miR-16 were mutated. The predicted minimum free energy values of
each hybrid are indicated, and the miR-16 binding sequences at the 3′-UTR of CDS2, PRDM4 and MAP7 are highly conserved across species.
(B) The identification of direct miR-16 targets by luciferase reporter screening. Firefly luciferase reporters containing the CDS2, PRDM4 or MAP7
3′-UTRs were co-transfected with pre-miR-16 or pre-miR-control into A549 cells. Luciferase reporters containing the 3′-UTRs of PPP1R11, CHUK,
LAMP2 and SLC35A4 served as negative controls. At 24 h post-transfection, cells were assayed using luciferase assay kits. The results are presented as
the mean ± SD of three independent experiments (** p < 0.01; *** p < 0.001). (C) Direct recognition of the 3′-UTRs of CDS2, PRDM4 and MAP7 by miR-
16. Firefly luciferase reporters containing either WT or MUT CDS2, PRDM4 or MAP7 3′-UTRs were co-transfected with pre-miR-16, pre-miR-control, anti-
miR-16 or anti-miR-control into A549 cells. At 24 h post-transfection, cells were assayed using luciferase assay kits. The results presented are
the mean ± SD of three independent experiments (*** p < 0.001).
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the miR-16–responsive 3′-UTRs were constructed and
transfected into A549 cells. The efficient overexpression
or knockdown of MAP7 (Figure 4, A and B) and PRDM4
(Additional file 1: Figure S1, C and D) is shown.
In supporting the notion that miR-16 is essential in
repressing proliferation, A549 cells transfected with anti-
miR-16 showed stimulation of cell proliferation; in con-
trast, overexpression of miR-16 had an opposite effect on
cell proliferation (Figure 4C). Furthermore, we assessed
the role of MAP7 and PRDM4 on cell proliferation. A549
cells transfected with a MAP7 overexpressing plasmid
proliferated at a significantly higher rate, whereas the
knockdown of MAP7 by siRNA significantly reduced
proliferation (Figure 4D). Finally, compared to cellstransfected with pre-miR-16, cells transfected with pre-
miR-16 and MAP7 overexpressing plasmid exhibited
significantly higher proliferation rates (Figure 4E),
suggesting that miR-16-resistant MAP7 could rescue
the suppression of MAP7 by miR-16. These results
demonstrate that miR-16 can inhibit cell proliferation
by silencing MAP7. On the other hand, no differences
were observed in proliferation rates between the cells
transfected with control siRNA or siRNA against
PRDM4 (Additional file 1: Figure S1E). The results sug-
gest that miR-16 could modulate cell proliferation by
downregulating genes other than PRDM4.
Next, we investigated apoptosis in cells with enhanced
miR-16 or silenced MAP7 or PRDM4 by flow cytometry
analysis. Statistically significantly more apoptotic cells
Figure 3 Regulation of MAP7 expression by miR-16 at both the transcript and protein levels. (A, D and G) Relative quantification RT-PCR
analysis of miR-16 levels in A549 (A), Hela (D) and MCF-7 (G) cells treated with pre-miR-16, pre-miR-control, anti-miR-16 or anti-miR-control. The
results presented are the mean ± SD of three independent experiments (*** p < 0.001). (B, E and H) Relative quantification RT-PCR analysis of
MAP7 mRNA levels in A549 (B), Hela (E) and MCF-7 (H) cells treated with pre-miR-16, pre-miR-control, anti-miR-16 or anti-miR-control. The results
presented are the mean ± SD of three independent experiments (*** p < 0.001). (C, F and I) Western blot analysis of MAP7 protein levels in A549
(C), Hela (F) and MCF-7 (I) cells treated with pre-miR-16, pre-miR-control, anti-miR-16 or anti-miR-control. Left panel: representative image; right
panel: quantitative analysis (*** p < 0.001).
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http://www.molecular-cancer.com/content/12/1/92were observed in the pre-miR-16-transfected cells com-
pared with pre-miR-control-transfected cells (Figure 4,
F and G). However, no differences in the levels of apop-
tosis were observed in cells transfected with negative
control siRNA or siRNA against MAP7 (Figure 4, F and
G). Likewise, silencing of PRDM4 had no effect on
apoptosis in A549 cells (Additional file 1: Figure S1, F
and G). These results suggest that miR-16 could trigger
apoptosis by downregulating genes other than MAP7
and PRDM4.
Finally, we investigated cell cycle distribution in cells
with enhanced miR-16 or silenced MAP7 or PRDM4 by
flow cytometry analysis. Compared with cells transfected
with pre-miR-control, cells transfected with pre-miR-16
triggered an accumulation of cells in the G0/G1 stage,
whereas the numbers of cells in the S and G2/M phasesdecreased (Figure 4, H and I). Transfection with siRNA
against MAP7 partially yielded the phenotype generated
by overexpression of miR-16, but the effects were not
significant, featured by a lower G0/G1 cell accumulation
but a higher S and G2/M cell accumulation (Figure 4, H
and I). Moreover, silencing of PRDM4 had no effect on
cell cycle progression of A549 cells (Additional file 1:
Figure S1, H and I). The results suggest that miR-16
might negatively regulate cell cycle progression from the
G0/G1 phase to the S phase by silencing genes other
than MAP7 and PRDM4.
Discussion
Although the number of known miRNAs is continuously
increasing, information regarding their precise cellular
function remains limited. One of the major challenges in
Figure 4 The role of miR-16 targeting MAP7 in the regulation of proliferation, apoptosis and cell cycle progression. (A and B) Efficient
overexpression or knockdown of MAP7 expression. For knockdown of MAP7, siRNA against MAP7 and a scrambled control siRNA were
transfected into A549 cells. For overexpression of MAP7, MAP7 overexpressing plasmid and an empty plasmid were transfected into A549 cells.
Cells were harvested at 24 h post-transfection. MAP7 mRNA and protein levels were assessed by relative quantification RT-PCR (A) and Western
blotting (B). Left panel: quantitative analysis; right panel: representative image. (C) MTT cell viability assay at 12, 24, 36, and 48 h after transfection
of A549 cells with equal doses of pre-miR-control, pre-miR-16, anti-miR-control or anti-miR-16. (D) MTT cell viability assay at 12, 24, 36, and 48 h
after transfection of A549 cells with equal doses of control siRNA or siRNA against MAP7 or equal doses of empty plasmid or MAP7
overexpressing plasmid. (E) MTT cell viability assay at 12, 24, 36, and 48 h after transfection of A549 cells with equal doses of pre-miR-control, pre-
miR-16, or pre-miR-16 along with the MAP7 overexpressing plasmid. (F) A549 cells transfected with equal doses of pre-miR-control, pre-miR-16, control
siRNA or siRNA against MAP7 were labeled with FITC-Annexin V/PI, and serum deprivation-induced apoptosis was measured by flow
cytometry. (G) Quantification of the apoptotic cells in panel F. (H) A549 cells were transfected with equal doses of scrambled ncRNA or pre-
miR-16 or equal doses of control siRNA or siRNA against MAP7. Cell cycle profiles were analyzed using flow cytometry. Shown in the panel are
histograms of cell numbers (y axis) against DNA content (x axis) determined by measuring fluorescence intensity. (I) Quantification of the
percentages of cells in the G0/G1, S, and G2/M phases in panel (H) (mean ± SD; ** p < 0.01; *** p < 0.001).
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http://www.molecular-cancer.com/content/12/1/92understanding the functions of a specific miRNA is to
identify its genuine target genes. To date, only a few
miRNAs have been assigned target mRNAs. In the
present study, we aimed to identify the genuine targets
of miR-16, a miRNA that has long been thought to be
implicated in tumorigenesis. By using microarray ana-
lysis to globally screen the expression patterns of tran-
scripts in several cell lines with overexpressed miR-16
and by combining bioinformatics programs to select
genuine miR-16 targets from the differentially regulated
genes, we identified a panel of 18 candidate miR-16 tar-
get genes. Actually, the same strategy has been used in
our earlier study [18]. In that study, in order to identify
the common targets of miR-16, we performed the
microarray analysis in A549, MCF-7 and HEK-293 cells
with either enhanced or silenced miR-16 [18]. In this
study, we re-performed the microarray analysis in A549,
MCF-7 and HEK-293 cells (we have re-performed the
whole procedure of the microarray analysis, from prep-
aration of new mRNA samples to analysis of new data),
as well as in additional HeLa and SW480 cells with en-
hanced miR-16. There are some overlap of microarray
data between this study and our earlier study. Among
the 27 mRNAs identified as downregulated in cells
overexpressing miR-16, nine (ARL2, CDS2, ANAPC13,
MAP7, ARG2, RTN4, RARS, SPRYD3 and RPS6KA3)
were also selected by our earlier study. The consistency
between these two studies further demonstrates the ro-
bustness of our strategy to identify the common miR-16
targets. On the other hand, the additional 18 mRNAs
identified as downregulated in this study were not ob-
served in the prior analysis. This may be due to the dif-
ferent criteria we used to select miR-16 targets. In our
previous study, only the mRNAs that showed consistent
downregulation (fold change < 0.66) in all three cell lines
were considered as candidate miR-16 targets. In the
present study, the mRNAs that showed downregulation
(fold change < 0.66) in at least four cell lines were con-
sidered as putative miR-16 targets. Thus, for mRNAs
such as NUPL1, TMEM109 and CCND3, because they
did not show significant downregulation in A549 cells,
they were not included as candidate miR-16 targets in
our previous study. However, in the present study they
were included because they showed downregulation in
other four cell lines. We have provided a table to
summarize the comparison findings between these two
studies (Additional file 1: Table S1).
Subsequently, we randomly selected three genes,
MAP7, PRDM4 and CDS2, from the candidate 18 genes
and used a luciferase reporter screen to experimentally
demonstrate that all three of these genes are directly
targeted by miR-16. Indeed, we demonstrated that miR-
16 regulates the expression of MAP7 and PRDM4 at
both the transcript and protein levels through severalbiological approaches. The results demonstrate that our
strategy of combining global gene expression analysis
with bioinformatics prediction may provide good selec-
tion criteria to aid in miRNA target identification.
We also showed that miR-16 could regulate cell prolif-
eration but not apoptosis and cell cycle progression in
A549 cells by silencing MAP7. However, how MAP7
regulates cell proliferation is currently unknown. MAP7
is a microtubule-associated protein that is predo-
minantly expressed in cells of epithelial origin [19].
Microtubule-associated proteins are involved in micro-
tubule dynamics, which are essential for many important
cellular processes including cell division, motility and
differentiation [19]. MAP7 has been shown to modulate
microtubule functions [19]. Thus, MAP7 may function
as a proliferation promoter through its role in the
microtubule dynamics. Furthermore, the role of MAP7
in cancer progression is also unclear. In support of a po-
tential role for MAP7 in metastatic growth, this gene
was recently identified as one out of only fifteen that
was highly upregulated in metastatic endometrial cancer
using a 22 K Affymetrix array [20]. Moreover, high
MAP7 expression has been associated with tumor recur-
rence and poor prognosis in Stage II colon cancer pa-
tients [21]. Here, we showed that MAP7 had the
potential to accelerate proliferation, but not influence
apoptosis and cell cycle progression in A549 cells. Al-
though we did not investigate the consequence of miR-
16 targeting MAP7 in other cancer cell lines, as miR-16
could regulate the expression of MAP7 in A549, HeLa
and MCF-7 cells, we speculate that miR-16 might have
similar cellular functions through silencing MAP7.
Therefore, the downregulation of miR-16 in cancer cells
would, in theory, relieve the suppression of miR-16 on
MAP7, which in turn accelerates tumorigenesis. The
modulation of MAP7 protein level by miR-16 may ex-
plain, at least in part, why the downregulation of miR-16
can promote cancer progression. Additional studies are
necessary to fully elucidate the exact roles of miR-16 in
regulating MAP7 in other cancer cells. Additional stud-
ies are necessary to uncover the clinical effects of miR-
16 in regulating MAP7 during cancer progression.
In this study, we uncovered multiple targets of miR-16
by combining mRNA microarray profiles with bioinfor-
matics analysis. We further experimentally validated
MAP7 as a direct target of miR-16 and demonstrated
that this targeting plays a critical role in regulating pro-
liferation in cancer cells.
Additional file
Additional file 1: Figure S1. Regulation of PRDM4 expression by miR-
16. (A) Relative quantification RT-PCR analysis of PRDM4 mRNA levels in
A549 cells treated with pre-miR-16, pre-miR-control, anti-miR-16 or anti-
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http://www.molecular-cancer.com/content/12/1/92miR-control. (B) Western blot analysis of PRDM4 protein levels in A549
cells treated with pre-miR-16, pre-miR-control, anti-miR-16 or anti-miR-
control. Left panel: representative image; right panel: quantitative analysis.
(C and D) Efficient overexpression or knockdown of PRDM4 expression.
For knockdown of PRDM4, siRNA against PRDM4 and a scrambled control
siRNA were transfected into A549 cells. For overexpression of PRDM4,
PRDM4 overexpressing plasmid and an empty plasmid were transfected
into A549 cells. Cells were harvested at 24 h post-transfection. PRDM4
mRNA and protein levels were assessed by relative quantification RT-PCR
(C) and Western blotting (D). Left panel: quantitative analysis; right panel:
representative image. (E) MTT cell viability assay at 12, 24, 36, and 48 h
after transfection of A549 cells with equal doses of control siRNA or
siRNA against PRDM4. (F) A549 cells transfected with equal doses of pre-
miR-control, pre-miR-16, control siRNA or siRNA against PRDM4 were
labeled with FITC-Annexin V/PI, and serum deprivation-induced apoptosis
was measured by flow cytometry. (G) Quantification of the apoptotic cells
in panel F. (H) A549 cells were transfected with equal doses of control
siRNA or siRNA against PRDM4. Cell cycle profiles were analyzed using
flow cytometry. Shown in the panel are histograms of cell numbers (y
axis) against DNA content (x axis) determined by measuring fluorescence
intensity. (I) Quantification of the percentages of cells in the G0/G1, S,
and G2/M phases in panel H. (mean ± SD; ** p < 0.01; *** p < 0.001).
Table S1. mRNAs identified as downregulated in cells overexpressing
miR-16 by this study and our previous study.Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
XC, YB and CYZ designed research and analyzed data. XY, HL, TD, KZ, SZ, NW
and XJ performed experiments. XW and RL performed statistical analysis. KZ
made contributions to the conception and design of experiments. XC and YB
wrote the manuscript. All authors read and approved the final manuscript.
Acknowledgements
This work was supported by grants from the National Natural Science
Foundation of China (Nos. 81101330, 81201946, 31271378 and 81250044)
and the Natural Science Foundation of Jiangsu Province (Nos. BK2011013
and BK2012014). This work was also supported by the program for New
Century Excellent Talents in University from the Ministry of Education, China
(NCET-09-0898 and NCET-12-0261).
Author details
1Tianjin Medical University Cancer Institute and Hospital, Huanhuxi Road,
Tiyuanbei, Tianjin 300060, China. 2Jiangsu Engineering Research Center for
microRNA Biology and Biotechnology, State Key Laboratory of Pharmaceutical
Biotechnology, School of Life Sciences, Nanjing University, 22 Hankou Road,
Nanjing 210093, China.
Received: 7 February 2013 Accepted: 13 August 2013
Published: 14 August 2013
References
1. Pasquinelli AE: MicroRNAs and their targets: recognition, regulation and
an emerging reciprocal relationship. Nat Rev Genet 2012, 13:271–282.
2. Peláez N, Carthew RW: Biological robustness and the role of microRNAs: a
network perspective. Curr Top Dev Biol 2012, 99:237–255.
3. Nana-Sinkam SP, Croce CM: Clinical applications for microRNAs in cancer.
Clin Pharmacol Ther 2013, 93:98–104.
4. Melo SA, Kalluri R: Molecular pathways: microRNAs as cancer
therapeutics. Clin Cancer Res 2012, 18:4234–4239.
5. Lages E, Ipas H, Guttin A, Nesr H, Berger F, Issartel JP: MicroRNAs: molecular
features and role in cancer. Front Biosci 2012, 17:2508–2540.
6. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan
S, Keating M, Rai K, Rassenti L, Kipps T, Negrini M, Bullrich F, Croce CM:
Frequent deletions and down-regulation of micro- RNA genes miR15
and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci
USA 2002, 99:15524–15529.7. Aqeilan RI, Calin GA, Croce CM: miR-15a and miR-16-1 in cancer:
discovery, function and future perspectives. Cell Death Differ 2010,
17:215–220.
8. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, Wojcik SE,
Aqeilan RI, Zupo S, Dono M, Rassenti L, Alder H, Volinia S, Liu CG, Kipps TJ,
Negrini M, Croce CM: miR-15 and miR-16 induce apoptosis by targeting
BCL2. Proc Natl Acad Sci USA 2005, 102:13944–13949.
9. Linsley PS, Schelter J, Burchard J, Kibukawa M, Martin MM, Bartz SR, Johnson
JM, Cummins JM, Raymond CK, Dai H, Chau N, Cleary M, Jackson AL,
Carleton M, Lim L: Transcripts targeted by the microRNA-16 family
cooperatively regulate cell cycle progression. Mol Cell Biol 2007,
27:2240–2252.
10. Liu Q, Fu H, Sun F, Zhang H, Tie Y, Zhu J, Xing R, Sun Z, Zheng X: miR-16
family induces cell cycle arrest by regulating multiple cell cycle genes.
Nucleic Acids Res 2008, 36:5391–5404.
11. Bonci D, Coppola V, Musumeci M, Addario A, Giuffrida R, Memeo L, D’Urso
L, Pagliuca A, Biffoni M, Labbaye C, Bartucci M, Muto G, Peschle C, De Maria
R: The miR-15a-miR-16-1 cluster controls prostate cancer by targeting
multiple oncogenic activities. Nat Med 2008, 14:1271–1277.
12. Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, Iorio MV,
Visone R, Sever NI, Fabbri M, Iuliano R, Palumbo T, Pichiorri F, Roldo C,
Garzon R, Sevignani C, Rassenti L, Alder H, Volinia S, Liu CG, Kipps TJ,
Negrini M, Croce CM: A MicroRNA signature associated with prognosis
and progression in chronic lymphocytic leukemia. N Engl J Med 2005,
353:1793–1801.
13. Bandi N, Zbinden S, Gugger M, Arnold M, Kocher V, Hasan L, Kappeler A,
Brunner T, Vassella E: miR-15a and miR-16 are implicated in cell cycle
regulation in a Rb-dependent manner and are frequently deleted or
down-regulated in non-small cell lung cancer. Cancer Res 2009,
69:5553–5559.
14. Huntzinger E, Izaurralde E: Gene silencing by microRNAs: contributions of
translational repression and mRNA decay. Nat Rev Genet 2011, 12:99–110.
15. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB: Prediction of
mammalian microRNA targets. Cell 2003, 115:787–798.
16. Krek A, Grün D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, MacMenamin P,
da Piedade I, Gunsalus KC, Stoffel M, Rajewsky N: Combinatorial microRNA
target predictions. Nat Genet 2005, 37:495–500.
17. John B, Enright AJ, Aravin A, Tuschl T, Sander C, Marks DS: Human
MicroRNA targets. PLoS Biol 2004, 2:e363.
18. Wang K, Li P, Dong Y, Cai X, Hou D, Guo J, Yin Y, Zhang Y, Li J, Liang H, Yu
B, Chen J, Zen K, Zhang J, Zhang CY, Chen X: A microarray-based
approach identifies ADP ribosylation factor-like protein 2 as a target of
microRNA-16. J Biol Chem 2011, 286:9468–9476.
19. Masson D, Kreis TE: Binding of E-MAP-115 to microtubules is regulated by
cell cycle-dependent phosphorylation. J Cell Biol 1995, 131:1015–1024.
20. Ferguson SE, Olshen AB, Viale A, Awtrey CS, Barakat RR, Boyd J: Gene
expression profiling of tamoxifen-associated uterine cancers: evidence
for two molecular classes of endometrial carcinoma. Gynecol Oncol 2004,
92:719–725.
21. Blum C, Graham A, Yousefzadeh M, Shrout J, Benjamin K, Krishna M, Hoda R,
Hoda R, Cole DJ, Garrett-Mayer E, Reed C, Wallace M, Mitas M: The
expression ratio of Map7/B2M is prognostic for survival in patients with
stage II colon cancer. Int J Oncol 2008, 33:579–584.
doi:10.1186/1476-4598-12-92
Cite this article as: Yan et al.: The identification of novel targets of miR-
16 and characterization of their biological functions in cancer cells.
Molecular Cancer 2013 12:92.
